RIVERMARK MEDICAL CLOSES $30 MILLION SERIES C FINANCING TO ADVANCE DEVELOPMENT OF FLOSTENT™ SYSTEM FOR BENIGN PROSTATIC HYPERPLASIANovel technology aims to provide immediate relief for patients while seamlessly integrating into routine urological visitsMILWAUKEE, October 10, 2024-- Rivermark Medical, a leader in minimally invasive solutions for Benign Prostatic Hyperplasia (BPH), today announced the close of a $30 million Series C financing round.

RIVERMARK MEDICAL结束了3000万美元的C系列融资，以推进用于良性前列腺增生的FLOSTENT™系统的开发。2024年10月10日，密尔沃基，RIVERMARK MEDICAL宣布结束3000万美元的C系列融资。

The round was led by American Century Investments (ACI) including new investors Venture Investors Health Fund, Time BioVentures, and an unnamed strategic investor, with follow-on participation from existing investors View Ventures, Cadence Healthcare Ventures, and Anduril Investors LLC..

本轮投资由美国世纪投资公司（ACI）牵头，其中包括新投资者风险投资健康基金、时代生物风险投资公司（Time BioVentures）和一位未具名的战略投资者，现有投资者View Ventures、Cadence Healthcare Ventures和Anduril investors LLC也参与了后续投资。

Funds will advance the clinical development of Rivermark's flagship product, the FloStent™ System, designed to restore urinary function for BPH patients. The device, currently in clinical development, offers a minimally invasive approach with quick recovery times, reversibility, and suitability for outpatient procedures..

资金将推动Rivermark旗舰产品FloStent™系统的临床开发，该系统旨在恢复BPH患者的泌尿功能。该设备目前正在临床开发中，提供了一种微创方法，具有快速恢复时间，可逆性和适合门诊手术的特点。

'We're grateful for the support of our investors as we progress toward bringing the FloStent System to market,' said Adam Kadlec, President and CEO of Rivermark Medical. 'This financing will accelerate our clinical programs and our path to commercialization, providing a new solution for the millions affected by BPH.'.

Rivermark Medical总裁兼首席执行官亚当·卡德拉克（AdamKadlec）说，在我们逐步将FloStent系统推向市场的过程中，我们感谢投资者的支持。

BPH is a non-cancerous condition caused by an enlarged prostate, impacting the quality of life in approximately 1 in 3 men over the age of 50. It can lead to uncomfortable symptoms such as frequent urination, difficulty urinating, and urinary tract infections (UTIs). Rivermark's FloStent System is a uniquely engineered nitinol stent that gently holds the prostatic urethra open to restore normal urinary flow while preserving sexual function.

BPH是一种由前列腺增大引起的非癌性疾病，影响了大约三分之一的50岁以上男性的生活质量。它会导致不舒服的症状，如尿频、排尿困难和尿路感染（UTI）。Rivermark的FloStent系统是一种独特的工程镍钛合金支架，可以轻轻地保持前列腺尿道的开放，以恢复正常的尿流，同时保持性功能。

The device is designed for rapid patient relief with minimal discomfort and can be deployed minimally invasively during an outpatient visit, offering fewer complications and minimal recovery time..

该设备设计用于快速缓解患者的不适感，可以在门诊就诊期间以微创方式部署，并发症少，恢复时间短。

'We believe Rivermark is poised to make a transformative impact on BPH treatment with their innovative FloStent System,' added Joe Biller, Managing Partner at American Century Investments. 'Existing therapies provide challenges for patients including a difficult recovery process, diminished sexual function, and irreversibility.

美国世纪投资公司（American Century Investments）管理合伙人乔·比勒（JoeBiller）补充说，我们相信，Rivermark将凭借其创新的FloStent系统对BPH治疗产生变革性影响现有疗法为患者提供了挑战，包括难以恢复的过程，性功能减退和不可逆性。

We're excited to support a technology that is uniquely engineered to address meaningful unmet needs.'.

我们很高兴能够支持一项独特的技术，以解决有意义的未满足需求。”

About Rivermark Medical

关于Rivermark Medical

Rivermark Medical was founded by a practicing urologist to develop the preferred first-line device therapy for benign prostatic hyperplasia. The FloStent System enables physicians to treat patients safely and efficiently, with minimal discomfort and reduced complications. The FloStent System was designed to rapidly restore normal urinary function, preserve sexual function, and improve a patient's overall quality of life.

Rivermark Medical由一位执业泌尿科医生创立，旨在开发治疗良性前列腺增生的首选一线设备。FloStent系统使医生能够安全有效地治疗患者，同时减少不适和并发症。FloStent系统旨在快速恢复正常的泌尿功能，保持性功能，并改善患者的整体生活质量。

The FloStent System is the first product Rivermark Medical plans to bring to market. For more information, please visit www.rivermarkmedical.com..

FloStent系统是Rivermark医疗计划推出的第一款产品。有关更多信息，请访问www.rivermarkmedical.com。